Granulocyte colony-stimulating factor in lung cancer

Research output: Contribution to journalArticle

Abstract

Hematopoietic growth factors, specifically G-CSF and GM-CSF, have proved to be effective in abrogating myelosuppression associated with cytotoxic chemotherapy. Both G-CSF and GM-CSF have been well tolerated although GM-CSF has been associated with more thrombocytopenia and a first dose reaction consisting of dyspnea, hypotension and tachycardia. G-CSF has clearly reduced the incidence of infection as manifested by fever during neutropenia in two placebo controlled prospective trials. Similar data are lacking for GM-CSF. Neither growth factor seems to have a clinically significant direct effect on lung cancer growth. However, further studies are necessary to clarify this issue given the conflicting in vitro data concerning growth stimulation. Further study also is needed to ascertain what impact, if any, the hematopoietic protective effect has on response and survival.

Original languageEnglish (US)
Pages (from-to)35-43
Number of pages9
JournalLung Cancer
Volume9
Issue number1-6
DOIs
StatePublished - 1993

Fingerprint

Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Lung Neoplasms
Intercellular Signaling Peptides and Proteins
Growth
Neutropenia
Tachycardia
Thrombocytopenia
Dyspnea
Hypotension
Fever
Placebos
Drug Therapy
Incidence
Infection

ASJC Scopus subject areas

  • Oncology

Cite this

Granulocyte colony-stimulating factor in lung cancer. / Johnson, David H.

In: Lung Cancer, Vol. 9, No. 1-6, 1993, p. 35-43.

Research output: Contribution to journalArticle

@article{9e01e13b84bd4af0873dd97ed722cff7,
title = "Granulocyte colony-stimulating factor in lung cancer",
abstract = "Hematopoietic growth factors, specifically G-CSF and GM-CSF, have proved to be effective in abrogating myelosuppression associated with cytotoxic chemotherapy. Both G-CSF and GM-CSF have been well tolerated although GM-CSF has been associated with more thrombocytopenia and a first dose reaction consisting of dyspnea, hypotension and tachycardia. G-CSF has clearly reduced the incidence of infection as manifested by fever during neutropenia in two placebo controlled prospective trials. Similar data are lacking for GM-CSF. Neither growth factor seems to have a clinically significant direct effect on lung cancer growth. However, further studies are necessary to clarify this issue given the conflicting in vitro data concerning growth stimulation. Further study also is needed to ascertain what impact, if any, the hematopoietic protective effect has on response and survival.",
author = "Johnson, {David H.}",
year = "1993",
doi = "10.1016/0169-5002(93)90652-E",
language = "English (US)",
volume = "9",
pages = "35--43",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1-6",

}

TY - JOUR

T1 - Granulocyte colony-stimulating factor in lung cancer

AU - Johnson, David H.

PY - 1993

Y1 - 1993

N2 - Hematopoietic growth factors, specifically G-CSF and GM-CSF, have proved to be effective in abrogating myelosuppression associated with cytotoxic chemotherapy. Both G-CSF and GM-CSF have been well tolerated although GM-CSF has been associated with more thrombocytopenia and a first dose reaction consisting of dyspnea, hypotension and tachycardia. G-CSF has clearly reduced the incidence of infection as manifested by fever during neutropenia in two placebo controlled prospective trials. Similar data are lacking for GM-CSF. Neither growth factor seems to have a clinically significant direct effect on lung cancer growth. However, further studies are necessary to clarify this issue given the conflicting in vitro data concerning growth stimulation. Further study also is needed to ascertain what impact, if any, the hematopoietic protective effect has on response and survival.

AB - Hematopoietic growth factors, specifically G-CSF and GM-CSF, have proved to be effective in abrogating myelosuppression associated with cytotoxic chemotherapy. Both G-CSF and GM-CSF have been well tolerated although GM-CSF has been associated with more thrombocytopenia and a first dose reaction consisting of dyspnea, hypotension and tachycardia. G-CSF has clearly reduced the incidence of infection as manifested by fever during neutropenia in two placebo controlled prospective trials. Similar data are lacking for GM-CSF. Neither growth factor seems to have a clinically significant direct effect on lung cancer growth. However, further studies are necessary to clarify this issue given the conflicting in vitro data concerning growth stimulation. Further study also is needed to ascertain what impact, if any, the hematopoietic protective effect has on response and survival.

UR - http://www.scopus.com/inward/record.url?scp=0027450729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027450729&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(93)90652-E

DO - 10.1016/0169-5002(93)90652-E

M3 - Article

AN - SCOPUS:0027450729

VL - 9

SP - 35

EP - 43

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1-6

ER -